Novartis

Novartis AG (NYSE: NVS) is a Swiss multinational pharmaceutical company. In 1996, the Swiss pharmaceutical companies Ciba-Geigy and Sandoz merged to form Novartis, considered the largest ever corporate merger at the time. The company has been listed on the NYSE since 2000. The company generated revenue of USD 45.4 billion in 2023 and was the ninth largest pharmaceutical manufacturer in the world by revenue.

Novartis operates under a single reporting segment, the Innovative Medicines business, since its Sandoz spinoff in October 2023.. The Innovative Medicines business segment researches, develops, manufactures, distributes, and sells patented pharmaceuticals. The segment focuses on core therapeutic areas—cardiovascular, renal and metabolic; immunology; neuroscience; oncology; and established brands.

Novartis products are sold in ~130 countries. The US was Novartis’ largest market, accounting for ~40% of total revenue in 2023, followed by Europe (~33%). Novartis’ strategic plan for 2024–2027 includes accelerating sales growth to 5% while maintaining an operating income margin of ~40%. The company is also committed to achieving net-zero status by 2040.